The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

What this study is testing ClinicalTrials.gov NCT01181986 ↗

Description as written by the study sponsor.

The purpose of this investigation is to evaluate whether exenatide, a type 2 diabetes medication, will improve the function of the innermost part of the arterial wall called the endothelium after a fat-enriched meal and to determine how this occurs. The results of this study will help to determine and understand a novel action of this group of diabetes medications based on the action of naturally occuring gut substances called incretins. This may have a significant impact on cardiovascular health in patients with early and longstanding diabetes.

Treatments tested

• Exenatide SC also known as Byetta, exendin-4 Drug

  Exenatide 5-10 ug sc BID/10 days

• Exenatide IV also known as exendin-4, Byetta Drug

  50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days

• Placebo SC also known as placebo Drug

  Placebo sc BID/10days

• Exendin-9 also known as exendin-(9-39) Drug

  Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.

• Placebo IV also known as placebo Drug

  Intravenous infusion for 45 minutes on 1 out of 3 visits